https://www.live-feeds.com/feed/astrazeneca-ceo-says-summit-drug-could-drive-next-generation-of-cancer-combinations-after-2-billion-investmentContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/astrazeneca-ceo-says-summit-drug-could-drive-next-generation-of-cancer-combinations-after-2-billion-investmenthttps://www.live-feeds.com/feed/astrazeneca-ceo-says-summit-drug-could-drive-next-generation-of-cancer-combinations-after-2-billion-investment#u110447Thu, 08 Oct 2026 10:47:17 +0000AstraZeneca has completed its equity investment of $2 billion in Summit Therapeutics and its bispecific antibody drug ivonescimab. AstraZeneca CEO Pascal Soriot stated that the asset could drive the next generation of cancer combinations. Alongside Daiichi Sankyo, AstraZeneca formed a clinical collaboration with Summit to evaluate ivonescimab in combination with Datroway across multiple tumour types. Soriot discussed the strategy from AstraZeneca's new R&D facility in Kendall Square in Cambridge, Massachusetts.Why it mattersThe massive financial commitment highlights big pharma's